^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD16 agonist

    Related drugs:
    3ms
    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=7, Terminated, Sanofi | N=18 --> 7 | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns
    Enrollment change • Trial termination
    |
    Venclexta (venetoclax) • azacitidine • IPH6101
    4ms
    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Sanofi | Trial completion date: Jun 2026 --> Aug 2025
    Trial completion date
    |
    Venclexta (venetoclax) • azacitidine • IPH6101
    5ms
    TCD17197: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (clinicaltrials.gov)
    P1/2, N=101, Terminated, Sanofi | N=169 --> 101 | Trial completion date: May 2029 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2028 --> May 2025; Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    IPH6101
    5ms
    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Jun 2026 | Trial primary completion date: Feb 2029 --> Oct 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • IPH6101
    7ms
    MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=1, Terminated, Masonic Cancer Center, University of Minnesota | N=33 --> 1 | Trial completion date: Sep 2028 --> Aug 2024 | Suspended --> Terminated | Trial primary completion date: Sep 2026 --> Aug 2024; Product withdrawn from clinical development
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    FT538 • enoblituzumab (MGA271)
    11ms
    TCD17197: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (clinicaltrials.gov)
    P1/2, N=169, Recruiting, Sanofi | Trial completion date: Oct 2030 --> May 2029 | Trial primary completion date: Dec 2025 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    IPH6101
    1year
    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Sanofi | Trial completion date: Feb 2029 --> Aug 2029
    Trial completion date
    |
    Venclexta (venetoclax) • azacitidine • IPH6101
    1year
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=9, Completed, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Oct 2024 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538
    1year
    TCD17197: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (clinicaltrials.gov)
    P1/2, N=169, Recruiting, Sanofi | N=126 --> 169 | Trial completion date: Nov 2026 --> Oct 2030
    Enrollment change • Trial completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    IPH6101
    over1year
    A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Sanofi
    New P1/2 trial
    |
    Venclexta (venetoclax) • azacitidine • IPH6101
    almost2years
    Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Masonic Cancer Center, University of Minnesota | N=34 --> 0
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Zolinza (vorinostat) • FT538
    almost2years
    MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=33, Suspended, Masonic Cancer Center, University of Minnesota | Recruiting --> Suspended
    Trial suspension
    |
    FT538 • enoblituzumab (MGA271)